Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | ACACA | Q13085 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ACP1 | P24666 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10199984 | 0.82 | SMN1; SMN2 (0.70) | SMN1; SMN2LMNAHPGDKDM4EALDH1A1 | |
| SCHEMBL955714 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAHPGDKDM4EALDH1A1 | |
| SCHEMBL2793755 | 0.79 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAHPGDKDM4EALDH1A1 | |
| SCHEMBL31529344 | 0.78 | LMNA (0.69) | SMN1; SMN2LMNAHPGDKDM4EALDH1A1 | |
| SCHEMBL4204786 | 0.78 | LMNA (0.64) | SMN1; SMN2LMNAHPGDKDM4EALDH1A1 | |
| SCHEMBL3975484 | 0.76 | ALOX15 (0.42) | SMN1; SMN2LMNAHPGDKDM4EALDH1A1 | |
| SCHEMBL3965450 | 0.76 | KDM4E (0.47) | SMN1; SMN2LMNAHPGDKDM4EALDH1A1 | |
| SCHEMBL3975907 | 0.76 | CYP1A2 (0.58) | SMN1; SMN2LMNAHPGDKDM4EALDH1A1 | |
| SCHEMBL28041155 | 0.76 | LMNA (0.65) | SMN1; SMN2LMNAHPGDKDM4EALDH1A1 | |
| SCHEMBL3967708 | 0.76 | ACHE (0.61) | SMN1; SMN2LMNAHPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
| US-6936620-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| WO-2003053940-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-$G(A) CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053941-A2 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003040103-A1 | β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | SMN1; SMN2 3011/4885LMNA 435/4885HPGD 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.